“… 4 , 16 For the 5 (29%) cases that presented with SEMP and had reported follow-up, there was no evidence of development of multiple myeloma after mean follow-up of 5 years (range 3–9 years). 6 , 8 , 11 , 12 , 17 For the 8 (47%) patients with multiple myeloma and reported follow-up, 4 (50%) patients died from multiple myeloma-associated complications, 3 (38%) patients had systemic disease improvement with treatment, and our case had systemic disease progression with local ocular tumor regression. 4 , 7 , 9 , 10 , 13 , 15 , 16 …”